However, considering that there were no differences in HER2-positivity between European and Asian countries based on the ToGA trial screening data (23.9% vs. 23.6%; n = 3665) and the Western patients more significantly responded to trastuzumab than the Eastern patients in the ToGA trial, we expect that DpR and ETS will be significant predictors of long-term outcomes among Western gastric cancer patients treated with trastuzumab as well. The gene discussed is ERBB2; the disease is gastric cancer.